Of 12 DLBCL lines insensitive to idelalisib (EC50 > 1 μM), none displayed a shift in sensitivity to the combination of PI3Kδ and PDK1/AKT inhibition (data not shown). This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.